基于肺可复张性的COVID-19相关ARDS个体化通气策略:一项前瞻性临床研究
该前瞻性临床研究连续纳入43例COVID-19相关ARDS患者,在仰卧/俯卧位与低PEEP(5 cmH2O)/高PEEP(15 cmH2O)组合下测量复张-膨胀比和电阻抗断层成像(EIT)区域肺膨胀。复张-膨胀比为0.68(IQR 0.52-0.84),据此区分高复张者与低复张者,两组氧合相同。高复张者高PEEP联合俯卧位氧合最高、EIT依赖区沉默空间最少(对比两种体位下的低PEEP),且不增加非依赖区沉默空间;低复张者俯卧位低PEEP氧合更好(对比仰卧位两种PEEP)、依赖区沉默空间更少(对比仰卧位低PEEP)、非依赖区沉默空间更少(对比两种体位下的高PEEP)。作者认为复张-膨胀比可能有助于COVID-19相关ARDS的PEEP个体化。
要点
- 连续纳入43例COVID-19相关ARDS患者,复张-膨胀比为0.68(IQR 0.52-0.84),以此区分高复张者与低复张者,两组氧合相同。
- 高复张者:高PEEP(15 cmH2O)联合俯卧位氧合最高、EIT依赖区沉默空间最少(对比两种体位下的低PEEP 5 cmH2O),且不增加非依赖区沉默空间。
- 低复张者:俯卧位低PEEP(5 cmH2O)氧合更好(对比仰卧位两种PEEP)、依赖区沉默空间更少(对比仰卧位低PEEP)、非依赖区沉默空间更少(对比两种体位下的高PEEP)。
- 应用高PEEP时,复张-膨胀比与氧合及呼吸系统顺应性改善、依赖区沉默空间减少呈正相关,与非依赖区沉默空间增加呈负相关。
适用人群与场景
- 连续纳入的COVID-19相关ARDS患者,共43例。
诊断标准与关键阈值
- 以复张-膨胀比0.68(IQR 0.52-0.84)区分高复张者与低复张者。
处置流程与药物剂量
- 测量组合:体位(仰卧或俯卧)与PEEP(低5 cmH2O或高15 cmH2O)组合下测量复张-膨胀比和EIT区域肺膨胀。
- 高复张者:高PEEP(15 cmH2O)联合俯卧位氧合最高、EIT依赖区沉默空间最少(对比两种体位下的低PEEP 5 cmH2O),且不增加非依赖区沉默空间。
- 低复张者:俯卧位低PEEP(5 cmH2O)氧合更好(对比仰卧位两种PEEP)、依赖区沉默空间更少(对比仰卧位低PEEP)、非依赖区沉默空间更少(对比两种体位下的高PEEP)。
研究设计与关键结果
- 研究类型:前瞻性临床研究;样本量:43例;人群:COVID-19相关ARDS患者。
- 复张-膨胀比为0.68(IQR 0.52-0.84),据此区分高复张者与低复张者;两组氧合相同。
- 高复张者:高PEEP(15 cmH2O)联合俯卧位氧合最高、EIT依赖区沉默空间最少(对比两种体位下的低PEEP 5 cmH2O),且不增加非依赖区沉默空间。
- 低复张者:俯卧位低PEEP(5 cmH2O)氧合更好(对比仰卧位两种PEEP)、依赖区沉默空间更少(对比仰卧位低PEEP)、非依赖区沉默空间更少(对比两种体位下的高PEEP)。
- 应用高PEEP时,复张-膨胀比与氧合及呼吸系统顺应性改善、依赖区沉默空间减少呈正相关,与非依赖区沉默空间增加呈负相关。
证据类型、等级与局限
- 证据类型:前瞻性临床研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为复张-膨胀比可能有助于COVID-19相关ARDS的PEEP个体化。
- 高复张者采用高PEEP(15 cmH2O)联合俯卧位、低复张者采用俯卧位低PEEP(5 cmH2O),分别减少依赖区沉默空间(提示肺塌陷)而不增加非依赖区沉默空间(提示过度膨胀)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Heterogeneity is an inherent nature of ARDS. Recruitment-to-inflation ratio has been developed to identify the patients who has lung recruitablity. This technique might be useful to identify the patients that match specific interventions, such as higher positive end-expiratory pressure (PEEP) or prone position or both. We aimed to evaluate the physiological effects of PEEP and body position on lung mechanics and regional lung inflation in COVID-19-associated ARDS and to propose the optimal ventilatory strategy based on recruitment-to-inflation ratio.
METHODS: Patients with COVID-19-associated ARDS were consecutively enrolled. Lung recruitablity (recruitment-to-inflation ratio) and regional lung inflation (electrical impedance tomography [EIT]) were measured with a combination of body position (supine or prone) and PEEP (low 5 cmH2O or high 15 cmH2O). The utility of recruitment-to-inflation ratio to predict responses to PEEP were examined with EIT.
RESULTS: Forty-three patients were included. Recruitment-to-inflation ratio was 0.68 (IQR 0.52-0.84), separating high recruiter versus low recruiter. Oxygenation was the same between two groups. In high recruiter, a combination of high PEEP with prone position achieved the highest oxygenation and less dependent silent spaces in EIT (vs. low PEEP in both positions) without increasing non-dependent silent spaces in EIT. In low recruiter, low PEEP in prone position resulted in better oxygenation (vs. both PEEPs in supine position), less dependent silent spaces (vs. low PEEP in supine position) and less non-dependent silent spaces (vs. high PEEP in both positions). Recruitment-to-inflation ratio was positively correlated with the improvement in oxygenation and respiratory system compliance, the decrease in dependent silent spaces, and was inversely correlated with the increase in non-dependent silent spaces, when applying high PEEP.
CONCLUSIONS: Recruitment-to-inflation ratio may be useful to personalize PEEP in COVID-19-associated ARDS. Higher PEEP in prone position and lower PEEP in prone position decreased the amount of dependent silent spaces (suggesting lung collapse) without increasing the amount of non-dependent silent spaces (suggesting overinflation) in high recruiter and in low recruiter, respectively.
参考来源
- Taenaka H, Yoshida T, Hashimoto H, et al. Personalized ventilatory strategy based on lung recruitablity in COVID-19-associated acute respiratory distress syndrome: a prospective clinical study. Crit Care. 2023. PMID: 37076900. doi:10.1186/s13054-023-04360-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。